If you've ever placed a limit order on an illiquid biotech option and watched it sit there all day before mysteriously filling at 3:55pm, you're not alone. After years of trading binary catalyst plays, I've pieced together how this game actually works—and where retail traders like us can find an edge.
Those Wide Bid/Ask Spreads Aren't Random
You pull up a small-cap biotech option chain and see a bid of $0.40 and an ask of $1.20. That $0.80 spread feels like highway robbery. But here's what's actually happening:
Those quotes are almost entirely from market makers—firms like Citadel Securities, Susquehanna, and Wolverine. They're required to provide continuous two-sided quotes in exchange for rebates and preferred exchange access. The $1.20 ask isn't what they expect to get. It's their "I'd love to get this" price. The real price is somewhere in between, and your job is to find it.
When you start bidding at $0.45 and slowly walk up to $0.50... then $0.55... eventually they fill you. You've just done price discovery. You found their actual indifference point—where their hedging math works and they're willing to trade.
How Market Makers Actually Make Money
Market makers aren't betting on whether your biotech gets approved. They're capturing the spread while staying directionally neutral. Here's the basic mechanics:
When they sell you a call option, they immediately buy shares of the underlying stock—enough to offset small price movements (this is called delta hedging). If the stock drifts up or down normally, they don't care. The shares offset the option exposure.
Their profit comes from that gap between where they buy and sell, repeated thousands of times daily across thousands of options. The edge per trade might be $5-15, but at scale it adds up.
The problem with biotech? Binary catalysts blow up their hedging models. A PDUFA result can gap a stock 50% overnight, and no amount of delta hedging saves you from that. Their hedge was sized for a $7 stock, not a $12 stock. That's why biotech spreads are so wide—it's compensation for gamma risk they can't hedge away.
The Information Asymmetry (It's Not as Bad as You Think)
Market makers have significant advantages:
- They see order flow through payment for order flow arrangements before it hits public exchanges
- They have the full depth of book while you see maybe 5-10 levels
- They're watching stock, options, and dark pools simultaneously
- Their servers sit inside the exchange building measuring latency in microseconds
But here's what matters: they're not your real opponent on the fundamental bet.
Market makers aren't doing what you're doing. They're not reading Phase 3 data, analyzing FDA briefing documents, checking AdCom voting history, or estimating probability of approval for specific indications. Their models say "binary event coming, price IV to compensate for gap risk." Your model says "this specific drug, this specific indication, this regulatory history—I think approval odds are 75% and options are priced for 55%."
They're pricing THAT an event happens. You're pricing WHAT happens.
They optimize for risk-adjusted returns across 50,000 option series. You're a specialist who knows 30 biotech names cold. Both are real edges—just different ones.
You're Playing Against the House, But the House is Okay With That
Think of it this way: you're a small leak in a very profitable boat.
Market makers segment order flow into "informed" and "uninformed." The trader buying 5 calls at the ask because he saw the ticker on social media? Uninformed. Pure profit for them. You, walking bids up patiently on a catalyst you've researched for weeks? Informed. They probably lose to you over time.
But they can't distinguish with certainty in real-time, and their math still works:
Say 100 retail traders interact with a biotech option in a month. If 90 are uninformed and the market maker profits $50 each, that's $4,500. If 10 are informed and the market maker loses $100 each, that's -$1,000. Net profit: $3,500.
They don't need to beat you. They need to beat the average. Your winners are subsidized by less sophisticated traders paying full ask prices.
The Art of Fishing with Limit Orders
My approach to illiquid options has become essentially fishing:
- Start your bid well below the ask—maybe 20-30% above the displayed bid
- Let it sit
- Walk it up slowly only if you need to
- Be patient
Why do orders often fill at end of day? Several reasons work in the market maker's favor:
- They're waiting to see if better bids come in
- Theta decay works for them by waiting
- By 3:30pm they know their overnight book and can decide if they want your exposure
- If your order is day-only, they have to act or lose the opportunity—they're calling your bluff
That instant fill when you bid just under the ask? That's information. You could have gone lower. Now you know.
Understanding IV: When Are Options Actually Cheap?
Implied volatility is the market's guess at how much a stock will move, annualized. For context on what's "normal":
- Large caps like AAPL or MSFT typically run 20-35% IV
- Normal small caps sit around 40-60%
- Biotechs with no near-term catalyst price at 50-80%
- Add a catalyst within three months: 80-150%
- Within weeks of a binary event: 150-300%+
- The day before a PDUFA? 300-500% isn't unusual
But "high IV" isn't the right question. The right question is: "Is IV high enough given what I expect to happen?"
If you believe a stock has 75% chance of approval and will hit $15 on that approval, you can calculate expected value. If IV is only pricing a move to $11, the options might be cheap even if the IV number looks scary.
The IV Crush Trap
This kills retail traders. Stock is at $7, IV is 150% before the PDUFA, you buy $10 calls for $1.50. Approval happens. Stock goes to $9.
You think you're making money. But IV collapses from 150% to 60% overnight. Your $10 calls are now worth $0.80. You were RIGHT on direction and still lost because you overpaid for volatility.
Your analysis needs to answer not just "will this approve?" but "will the move exceed what IV implies?"
The Bottom Line
You're not trying to beat market makers at their game—speed, infrastructure, and information flow. You're playing a different game entirely. They're the tollbooth. You're trying to minimize the toll while making the right directional bets.
The edge for retail biotech traders comes from:
- Deep fundamental research on specific catalysts
- Patience in execution
- Understanding that the market maker isn't your opponent on the core thesis
- Recognizing that your winners are effectively subsidized by less sophisticated flow
Do the work. Fish patiently. And remember—that wide bid/ask spread isn't a wall, it's a negotiation.